Llwytho...

Trastuzumab-DM1: A Clinical Update of the Novel Antibody-Drug Conjugate for HER2-Overexpressing Breast Cancer

Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor. Although trastuzumab is a very active agent in HER2-overexpressing breast cancer, the majority of patients with metastatic HER2-overexpressing breast cancer who initially respond to trastuzumab develop resistanc...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Barginear, Myra F, John, Veena, Budman, Daniel R
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: ScholarOne 2012
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3563710/
https://ncbi.nlm.nih.gov/pubmed/23196784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2119/molmed.2012.00302
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!